Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 7/20 | 0.66 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.66 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.66 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10830248 | 1.00 | CACNA1F (0.66) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL3027412 | 0.84 | ADORA3 (0.89) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10901491 | 0.84 | CACNA1F (0.66) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7044551 | 0.84 | ALDH1A1 (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7048693 | 0.84 | ALDH1A1 (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7048080 | 0.84 | ALDH1A1 (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7044561 | 0.84 | ALDH1A1 (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10830230 | 0.83 | ADORA3 (0.68) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10830852 | 0.83 | ADORA3 (0.72) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10829909 | 0.83 | ADORA3 (0.61) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | ACIN1, DNA2, KPNA1 | CACNA1F 1704/4885CACNA1D 1123/4885CACNA1S 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.